Keros Therapeutics is ending development of a phase 2 candidate designed to treat high blood pressure in the lungs, a move that has triggered layoffs for 45% of the biotech’s team.
https://www.fiercebiotech.com/biotech/keros-culls-pah-asset-prompting-layoffs-70-workers